Figure 4.

NK-92 therapy of primary acute myeloid leukemia (AML) xenografted NOD/SCID gamma^null (NSG) mice. 3×10⁶ primary AML cells were injected intravenously (i.v.) via tail vein into irradiated NOD/SCID gamma null mice to establish disease in control (n=5) and therapy mice (n=10). 10×10⁶ NK-92 were infused via tail vein weekly for three weeks starting on the day of AML inoculation in treatment group (A). Mice were monitored for signs of leukemia and sacrificed at humane end points. Kaplan-Meier survival curves were generated to compare survival in control and treatment groups (P<0.01) (B).